James Paton And Robert Langreth Bloomberg

A drug from AstraZeneca Plc and Daiichi Sankyo Co. extended the lives of patients with an advanced form of breast cancer by about six months in a late-stage trial that may widen the population of people who can benefit from the treatment.

In early January, about the only thing the world's scientists knew for sure about the novel coronavirus was its genetic profile. Now, some 300 days later, vaccine developers are on the brink of a major victory against a pathogen that's inflicted untold personal and economic damage.

A drug from AstraZeneca Plc and Daiichi Sankyo Co. extended the lives of patients with an advanced form of breast cancer by about six months in a late-stage trial that may widen the population of people who can benefit from the treatment.

In early January, about the only thing the world's scientists knew for sure about the novel coronavirus was its genetic profile. Now, some 300 days later, vaccine developers are on the brink of a major victory against a pathogen that's inflicted untold personal and economic damage.